Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 4/20 | 0.55 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.50 |
| ▸ | MCOLN1 | Q9GZU1 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21244042 | 0.89 | ALDH1A1 (0.52) | MAPTHTTMCOLN3PKML3MBTL1 | |
| SCHEMBL21244051 | 0.89 | MCOLN3 (0.55) | MAPTMCOLN3PKML3MBTL1ALDH1A1 | |
| SCHEMBL21244039 | 0.88 | MAPT (0.46) | MAPTHTTMCOLN3PKML3MBTL1 | |
| SCHEMBL21244038 | 0.87 | ALDH1A1 (0.54) | MAPTHTTMCOLN3PKML3MBTL1 | |
| SCHEMBL21244034 | 0.87 | L3MBTL1 (0.53) | MAPTHTTMCOLN3PKML3MBTL1 | |
| SCHEMBL21244031 | 0.86 | MCOLN3 (0.52) | MAPTMCOLN3PKML3MBTL1ALDH1A1 | |
| SCHEMBL21244035 | 0.86 | MAPT (0.52) | MAPTHTTL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL21244040 | 0.85 | ALDH1A1 (0.57) | MAPTHTTMCOLN3PKML3MBTL1 | |
| SCHEMBL21244029 | 0.84 | ALDH1A1 (0.54) | MAPTHTTMCOLN3PKML3MBTL1 | |
| SCHEMBL29931981 | 0.81 | MCOLN2 (0.47) | MAPTHTTMCOLN3PKML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851084-B2 | Piperazine derivatives as TRPML modulators | Lysoway Therapeutics, Inc. (US) | 2020-12-01 | — | — | US | claimed |
| US-20190248764-A1 | PIPERAZINE DERIVATIVES AS TRPML MODULATORS | CalyGene Biotechnolgy, Inc. (US) | 2019-08-15 | — | — | US | claimed |
| US-10851084-B2 | Piperazine derivatives as TRPML modulators | Lysoway Therapeutics, Inc. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851084-B2 | Piperazine derivatives as TRPML modulators | Lysoway Therapeutics, Inc. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190248764-A1 | PIPERAZINE DERIVATIVES AS TRPML MODULATORS | CalyGene Biotechnolgy, Inc. (US) | 2019-08-15 | — | — | US | disclosed |
| US-20190248764-A1 | PIPERAZINE DERIVATIVES AS TRPML MODULATORS | CalyGene Biotechnolgy, Inc. (US) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851084-B2 | Piperazine derivatives as TRPML modulators | TRPM5, TRPM2, TRPM4 | MAPT 577/4885HTT 531/4885MCOLN3 9/4885 |
| US-20190248764-A1 | PIPERAZINE DERIVATIVES AS TRPML MODULATORS | TRPM5, TRPM2, TRPM4 | MAPT 577/4885HTT 531/4885MCOLN3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.